ATE494361T1 - Nierenkarzinomzellinie und verwendung davon - Google Patents
Nierenkarzinomzellinie und verwendung davonInfo
- Publication number
- ATE494361T1 ATE494361T1 AT06807444T AT06807444T ATE494361T1 AT E494361 T1 ATE494361 T1 AT E494361T1 AT 06807444 T AT06807444 T AT 06807444T AT 06807444 T AT06807444 T AT 06807444T AT E494361 T1 ATE494361 T1 AT E494361T1
- Authority
- AT
- Austria
- Prior art keywords
- cells
- cell line
- renal carcinoma
- immune system
- carcinoma cell
- Prior art date
Links
- 208000006265 Renal cell carcinoma Diseases 0.000 title abstract 4
- 206010038389 Renal cancer Diseases 0.000 title abstract 2
- 201000010174 renal carcinoma Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 7
- 210000000987 immune system Anatomy 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002018A ITMI20052018A1 (it) | 2005-10-21 | 2005-10-21 | Linea cellulare di carcinoma renale e suo uso |
| PCT/EP2006/067631 WO2007045691A2 (en) | 2005-10-21 | 2006-10-20 | Renal carcinoma cell line and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE494361T1 true ATE494361T1 (de) | 2011-01-15 |
Family
ID=37814004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06807444T ATE494361T1 (de) | 2005-10-21 | 2006-10-20 | Nierenkarzinomzellinie und verwendung davon |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8128923B2 (de) |
| EP (1) | EP1957631B1 (de) |
| AT (1) | ATE494361T1 (de) |
| DE (1) | DE602006019485D1 (de) |
| IT (1) | ITMI20052018A1 (de) |
| NO (1) | NO341903B1 (de) |
| WO (1) | WO2007045691A2 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130006878A1 (en) * | 2011-06-30 | 2013-01-03 | International Business Machines Corporation | Nanostructure tracking of product data signatures |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1326961B1 (de) * | 2000-09-15 | 2007-08-22 | Ortho-McNeil Pharmaceutical, Inc. | Zusammensetzungen und verfahren zur auslösung spezifischer zytolytischer t-zellantworten |
-
2005
- 2005-10-21 IT IT002018A patent/ITMI20052018A1/it unknown
-
2006
- 2006-10-20 AT AT06807444T patent/ATE494361T1/de not_active IP Right Cessation
- 2006-10-20 DE DE602006019485T patent/DE602006019485D1/de active Active
- 2006-10-20 US US12/083,842 patent/US8128923B2/en active Active
- 2006-10-20 WO PCT/EP2006/067631 patent/WO2007045691A2/en active Application Filing
- 2006-10-20 EP EP06807444A patent/EP1957631B1/de active Active
-
2008
- 2008-05-19 NO NO20082287A patent/NO341903B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO341903B1 (no) | 2018-02-19 |
| NO20082287L (no) | 2008-05-19 |
| WO2007045691A3 (en) | 2007-07-26 |
| EP1957631A2 (de) | 2008-08-20 |
| US8128923B2 (en) | 2012-03-06 |
| WO2007045691A8 (en) | 2008-06-19 |
| WO2007045691A2 (en) | 2007-04-26 |
| US20090136458A1 (en) | 2009-05-28 |
| DE602006019485D1 (de) | 2011-02-17 |
| ITMI20052018A1 (it) | 2007-04-22 |
| EP1957631B1 (de) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oderup et al. | Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppression | |
| Serafini et al. | Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells | |
| MY198084A (en) | Expansion of non-haematopoietic tissue-resident ()()t cells and uses of these cells | |
| WO2006002377A3 (en) | Optimized dosing with anti-cd4 antibodies for tolerance induction in primates | |
| IL189143A0 (en) | Use of common ?? chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes | |
| WO2005004592A8 (en) | Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications | |
| WO2007044418A3 (en) | Cell culture media, kits and methods of use | |
| AU2008326599A8 (en) | Modulation of the immune response | |
| IL218447A0 (en) | Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais) | |
| WO2005000348A3 (en) | Vaccines inducing nkt-cell and toll-like-receptor activation | |
| Eggermont et al. | Cytokine‐functionalized synthetic dendritic cells for T cell targeted immunotherapies | |
| ATE435508T1 (de) | Bipolare doppelfunktionstrennplatten für brennstoffzellen | |
| WO2003038062A3 (en) | Generation of use of tc1 and tc2 cells | |
| ATE494361T1 (de) | Nierenkarzinomzellinie und verwendung davon | |
| Dukers et al. | Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype | |
| CY1109815T1 (el) | Μεθοδοι διασταυρουμενης συμβατοτητας ειδικες δοτη | |
| GB0325346D0 (en) | Oligomeric receptor ligand pair member complexes | |
| ATE346140T1 (de) | Gen 2.2 dendritische zell linien | |
| CL2008001449A1 (es) | Metodo para estimular la produccion de celulas hematopoyeticas diferenciadas en un cultivo que comprende celulas progenitoras hematopoyeticas, linfocitos y monocitos/macrofagos y/o celulas dendriticas en presencia de una molecula de union especifica para una molecula coestimuladora expresada en dichas celulas. | |
| DK1218028T3 (da) | Dendritiske celler som bliver aktiveret i tilstedeværelsen glucocorticoidhormoner er i stand til at undertrykke antigenspecifikt T-cellerespons | |
| 李金锋 | The prognostic value of various lymphocyte in clear cell renal cell carcinoma | |
| Schuetz et al. | A new flow cytometric assay for the simultaneous analysis of antigen specific elimination of T cells in heterogenous T cell populations | |
| Fehrenbach et al. | Bone Marrow Transfer from Rats Fed Low or High Salt Diets Does Not Influence Salt‐Sensitive Blood Pressure and Kidney Disease in Dahl SS Recipient Rats | |
| Giannopoulos et al. | Involvement Of Autoreactive T Lymphocytes In Pathogenesis Of Chronic Lymphocytic Leukemia (CLL): Specific T-Cell Immune Responses Against Autoantigens Recognized By CLL Cells | |
| Pourgheysari et al. | Significance of CMV-seropositivity in the alterations of CD4+ T-cell subsets and expression of their phenotyping markers in B-cell chronic lymphocytic leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |